Evidence map›Paper›PMID 38693745›Full record

ReviewCurrent vascular pharmacology2024

Cellular and Molecular Mechanisms of Neuronal Degeneration in Early-Stage Diabetic Retinopathy.

Andrew Callan, Sonal Jha, Laura Valdez, Andrew Tsin

Abstract readReview
In one paragraph

Review in Current vascular pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Vacuolar protein sorting 35 regulates retinal neurovascular functionInternational journal of ophthalmology · 2026
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Andrew CallanDepartment of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, USA.
Sonal JhaDepartment of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, USA.
Laura ValdezDepartment of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, USA.
Andrew TsinDepartment of Neuroscience, School of Medicine, University of Texas Rio Grande Valley, USA.
The University of Texas Rio Grande Valley · US

Funding

Cell-Meditated Inflammatory Pathway and Diabetic RetinopathyR15EY033551 · NEI · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI TSIN, ANDREW T C · 2022 to 2023
$624k
NEI NIH HHS R15 EY033551NIH, National Institutes of Health EY033551, CA278054, DA056203, AG059305
6 · The paper itself

Abstract

backgroundStudies on the early retinal changes in Diabetic Retinopathy (DR) have demonstrated that neurodegeneration precedes vascular abnormalities like microaneurysms or intraretinal hemorrhages. Therefore, there is a growing field of study to analyze the cellular and molecular pathways involved to allow for the development of novel therapeutics to prevent the onset or delay the progression of DR. Molecular Mechanisms: Oxidative stress and mitochondrial dysfunction contribute to neurodegeneration through pathways involving polyol, hexosamine, advanced glycation end products, and protein kinase C. Potential interventions targeting these pathways include aldose reductase inhibitors and protein kinase C inhibitors. Neurotrophic factor imbalances, notably brain-derived neurotrophic factor and nerve growth factor, also play a role in early neurodegeneration, and supplementation of these neurotrophic factors show promise in mitigating neurodegeneration. Cellular Mechanisms: Major cellular mechanisms of neurodegeneration include caspase-mediated apoptosis, glial cell reactivity, and glutamate excitotoxicity. Therefore, inhibitors of these pathways are potential therapeutic avenues. Vascular Component: The nitric oxide pathway, critical for neurovascular coupling, is disrupted in DR due to increased reactive oxygen species. Vascular Endothelial Growth Factor (VEGF), a long-known angiogenic factor, has demonstrated both damaging and neuroprotective effects, prompting a careful consideration of long-term anti-VEGF therapy.

conclusionCurrent DR treatments primarily address vascular symptoms but fall short of preventing or halting the disease. Insights into the mechanisms of retinal neurodegeneration in the setting of diabetes mellitus not only enhance our understanding of DR but also pave the way for future therapeutic interventions aimed at preventing disease progression and preserving vision.

Indexed as

Diabetic RetinopathyOxidative StressSignal TransductionAnimalsApoptosisHumansMitochondriaNerve DegenerationNeuroprotective AgentsRetinal DegenerationRetinal NeuronsNeuroprotective Agentsapoptosis.diabetes mellitusDiabetic retinopathyglial cellsneurodegenerationpathophysiologyretina

Identifiers

PMID38693745
PMCPMC13237750
OpenAlexW4396590490

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.